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The three envelope proteins of the hepatitis B virus (HBV) are encoded by a single open reading frame in the genome
containing three separate in-phase AUG codons. This organization defines three protein domains (pre-S1, pre-S2, S) which
form the small (S), middle (M, pre-S2/S), and large (L, pre-S1/pre-S2/S) proteins. Mature virions are generated by the budding
of preformed nucleocapsids through endoplasmic reticulum (ER) membranes containing S and L proteins, whereas the M
protein is not necessary. This suggests an important function for the pre-S1 domain. To investigate the protein–protein
interactions involved during the maturation process of the HBV virion, we studied in vitro the binding affinity to purified HBV
core particles of various synthetic peptides identical to regions of the envelope proteins. Data previously obtained with
deletion mutants were confirmed and refined. The 13 C-terminal amino acids of pre-S1 bound efficiently to core particles,
whereas other pre-S domains did not. Moreover, the amino acid sequence 56–80 in the cytosolic loop of S bound efficiently
to the HBV core. This double interaction between the HBV capside and both S and pre-S1 domains may be required for
virion morphogenesis. q 1997 Academic Press
Hepatitis B virus (HBV) is an enveloped DNA virus of major constituent of both virion and empty particle enve-
lopes (6). L protein is necessary for virion maturation,the Hepadnavirus family which causes a variety of acute
and chronic liver diseases in humans (reviewed in Ref. 1 and S is required but not sufficient (3, 7, 8). M seems to
be dispensable (3, 7). S protein is unique among viraland 2). Its genome is encapsidated with a virus-encoded
envelope proteins in its capacity to self-assemble withpolymerase in a 27-nm diameter nucleocapsid sur-
host-derived lipids into secreted empty envelope parti-rounded by a host-derived lipid envelope bearing three
cles (9). It has a type I signal at its N terminus and anviral surface proteins. The mature 42-nm virion is formed
internal type II signal which result in the protein to tra-by a preformed cytosolic nucleocapsid interacting with
verse the membrane at least twice and form a cytosolicsurface proteins anchored in a pre-Golgi membrane and
loop and a luminal domain (reviewed in Ref. 10). The C-is secreted by the constitutive secretory pathway (3–5).
terminus of S is very hydrophobic and is believed to beThe three HBV surface proteins are translated from a
embedded in the lipid bilayer (Fig. 1). L protein can adoptsingle open reading frame of the viral genome from three
two different trans-membrane topologies (11–13). Thedifferent in-phase start codons. Therefore the 226 amino
first called e-pre-S has pre-S domains on the luminalacid sequence of the small (S) protein is repeated at the
side of the ER. After budding, pre-S domains becomeC termini of the middle (M) and the large (L) surface
exposed on the surface of secreted virions and capableproteins, which carry the additional N-terminal 55 amino
of binding to a virus receptor (14). The second called i-acid pre-S2 domain and the 163 amino acid (subtypes
pre-S has the pre-S domain on the cytosolic side of theayw) pre-S2 plus pre-S1 domain, respectively (6). In addi-
ER (Fig. 1) thus providing a specific interaction with HBVtion to the virion, HBV surface proteins can also be inde-
nuceocapsid during virion assembly (7). This specific in-pendently secreted from cells as 22-nm diameter spheri-
teraction has been investigated by testing the ability ofcal or tubular subviral particles. These empty particles
various truncated L mutants to form virions. Thus, the 17are found at much higher serum concentrations than
C-terminal amino acids of the pre-S1 domain (aa 91 tovirions and consist of host lipids and viral envelope pro-
108 in the ayw subtype) are essential for virion formation,teins without any other viral component. S protein is the
whereas the N-terminal 5/6 of the pre-S1 sequence are
not required for this process (7). The S protein is also
necessary for virion maturation but its exact function has1 To whom correspondence and reprint requests should be ad-
dressed. Fax: (33) 2 47 36 60 90. E-mail: Roingeard@univ-tours.fr. not been determined. It is unclear whether S interacts
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the first 10 aa of peptide L4) and peptide 4b (the last 13
aa of peptide L4 plus the first 8 peptides of pre-S2) (Fig.
1). All peptides were synthesized with an automated pep-
tide synthesizer (Applied Biosystems 431A) by the solid-
phase procedure developed by Merrifield (16), with 9-
fluorenyl-methoxycarbonyl-protected amino acids and p-
hydroxymethyl-phenoxyacetic resin. After synthesis, the
resin support and the side chain-protecting groups were
removed by treatment with trifluoroacetic acid in the
presence of scavengers. Peptides were purified by re-
verse-phase chromatography on C8 columns (Aquapore
octyl; 20 mm; 100 by 10 mm; Applied Biosystems) and
characterized by amino acid analysis (17).
Purification of HBV core particles: Human HBcAg-posi-
tive tissue obtained from a liver necropsy was homoge-
nized in a gentle lysis buffer (10 mM Tris–HCl, pH 7.2,
150 mM NaCl, 0.1 mM EDTA, 0.1% NP-40, 0.05% 2 b-
mercaptoethanol). Cell fragments were removed by cen-
trifugation at 10,000 rpm for 30 min at 47C. The superna-
tant was spun on a isopycnic 24 to 64% sucrose gradient
(wt/vol in 150 mM NaCl, 20 mM Tris–HCl, pH 7.4) at
22,000 rpm for 36 hr in a SW 28 swinging rotor (Beckman,
Somerset, NJ). Fractions were tested for the presence
of HBV core particles by HBcAg-specific enzyme-linked
immunoassay (ELISA) as described elsewhere (18).FIG. 1. Amino acid sequence (ayw subtype) of the 9 synthetic pep-
Briefly, the IgG fraction from a selected human serumtides covering HBV S and L surface protein domains exposed on the
cytosolic side of the ER. The small HBV surface protein (S, 226 aa) [anti-HBc positive up to the 1007 dilution, anti-HBe and
spans the membrane at its N-terminal type I and the central type II anti-HBs negative (all tests from Abbott lab., North Chi-
signals (open boxes) and probably twice at its hydrophobic C-terminal
cago, IL)] was used as the solid phase. Dynatech ELISAregion. S exposes a loop of 50 amino acids at the cytosolic side of ER,
plates were coated with this IgG preparation (1 mg/ml)covered by peptides S1 and S2. The large HBV surface protein (L)
diluted 1/500 in 0.1 M carbonate buffer, pH 9.2, incubatedcontains the 226 aa of S plus 163 aa called the pre-S domain at its N-
terminus. This pre-S domain has two subdomains: pre-S1, containing overnight at 47 and then washed four times with a wash-
108 aa (peptides L1, L2, L3, and L4); and pre-S2, containing 55 aa ing buffer [phosphate-buffered saline (PBS), pH 7.2, con-
(peptide L5). The L protein adopts two membrane topologies (11): the
taining 0.1% Tween 20]. To avoid nonspecific adsorbtion,e-pre-S L form (not shown in this figure) displaying the N-terminal pre-
plates were coated with a 5% solution of dry nonfat milkS domain at the ER lumen, and the i-pre-S L form (presented in the
in PBS, incubated for 1 hr at 377, and then washed withfigure), exposing the pre-S domain and the N-terminal part of the S
domain of L up to signal II on the cytosolic side of ER. the washing buffer. Fractions were diluted 1/500 in a
dilution buffer [PBS containing 0.05% Tween and 2% milk
powder] then added to the wells and incubated for 3 hr
with L, with the HBV core or with both during particle at 377. After four washes, the plates were incubated for
assembly. In this work, pre-S1, pre-S2, and the cytosolic 1 hr at 377 with the monoclonal anti-HBc antibody 6C6A1
loop of S were mapped in synthetic peptides which were (18) diluted 1/1000 in the dilution buffer, then washed
tested for their ability to bind purified liver-derived HBV four times and incubated for 1 hr at 377 with peroxidase-
core particles. conjugated goat anti-mouse IgG (Cappel, West Chester,
S and L peptides synthesis: Peptides corresponding PA) diluted 1/2000 in dilution buffer. After four washes,
to pre-S1, pre-S2, and the cytosolic loop of S were synthe- the peroxidase reaction was performed by adding a mix-
sized as shown in Fig. 1. The amino acid sequence was ture of hydrogen peroxide/o-phenylenediamine substrate
obtained from the Swiss-prot database (AC P03138), cor- (Sigma, St-Louis, MO) and incubating for 30 min in the
responding to the ayw subtype DNA sequence published dark. The reaction was stopped with 4 N H2SO4 and
by Galibert et al. (15). The cytosolic loop of S was covered the optical density at 492 nm was determined with a
by two 25 amino acid peptides, S1 and S2. The pre-S1 microplate reader.
domain was covered by four peptides of 28, 28, 29, and HBc Ag-positive fractions were pooled, dialyzed
23 amino acids named L1, L2, L3, and L4, respectively. against 25 mM Tris–HCl, pH 8.5, 50 mM NaCl, and the
Pre-S2 was covered by a single 55 amino acids peptide, preparation was further purified by a ion-exchange chro-
L5. Two additional peptides overlapping peptide L4 were matography on a DEAE-trysacryl M gel (LKB, Bromma,
Sweden). A discontinuous NaCl gradient (0.15 M/0.3 M/synthesized: peptide 4a (the last 10 aa of peptide L3 plus
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1 M) was used for elution. The total protein concentration Binding of envelope peptides to core particles: Binding
was first evaluated as the ability of the peptides to inhibitin fractions was determined by measuring the optical
density at 280 nm and HBc Ag activity assayed in 1/400 core particle capture by the HBcAg-specific immunoas-
say. To obtain a reproducible optical density value of 2.5dilutions by ELISA as described above (Fig. 2). Fractions
30 to 37 were pooled and concentrated 10-fold by centrif- in control wells (without peptide), the assay was slightly
modified as follows. Human anti-HBc IgG diluted 1/500ugation at 25,000 rpm for 6 hr (47, rotor SW 28, Beckman).
This final core particle preparation contained 0.4 mg/ml dilution in 50 mM bicarbonate buffer, pH 9.6, were coated
onto polystyrene plates (Maxisorp, Nunc, Naperville, IL),of protein and the specific activity measured with 1/2
serial dilutions by HBcAg ELISA was 28 per mg of protein. for 20 hr at 47 (100 ml per well). The HBV core preparation
was diluted 1/100 in 1 mM PBS, 15 mM NaCl, pH 7.4,HBV core particles of 28 to 32 nm diameter were ob-
served by electron microscopy (Jeol 1200 EX, Tokyo) after and incubated for 20 hr at 47 with each of a series of
concentrations (0 to 100 mg/ml) of each peptide in thenegative staining with 2% uranyl acetate.
FIG. 2. Purification of HBV core particles from a human liver. Top, elution profile of the ion-exchange chromatography on DEAE-trysacryl M gel.
A discontinuous NaCl gradient (0.15 M/0.3 M/1 M) was used for elution. Most contaminant proteins as assessed by following the optical density
(OD) at 280 nm were collected at the 0.15 M elution. HBc Ag activity determined by a specific immunoassay (OD at 492 nm) was detected in
fractions collected during the 0.3 M NaCl elution. Bottom, pooled and concentrated HBc Ag-positive fractions examined by negative staining under
an electron microscope showing intact HBV core particles.
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same buffer. Plates were washed three times with 0.01 washed three times with 0.01 M PBS, 0.15 M NaCl, pH 7.4,
containing 0.5% Tween 20, and blocked by the addition ofM PBS, 0.15 M NaCl, pH 7.4, containing 0.5% Tween 20
and blocked by the addition of 300 ml of PBS containing 300 ml of PBS containing 2% newborn calf serum (NBCS)
incubated for 45 min at 377. After one wash, the HBV core2% newborn calf serum (NBCS) incubated for 45 min at
377. The mixed core particles/peptide preparations were preparation diluted 1/50 in 1 mM PBS, 15 mM NaCl, pH
7.4, was incubated for 24 hr at 47. The other steps for corethen added to the wells and incubated for 1 hr at room
temperature. After three washes, 100 ml of monoclonal particles detection (monoclonal anti-HBc and peroxidase-
conjugated goat anti-mouse incubations) were performedanti-HBc 6C6A1 diluted 1/10,000 in 0.05 M PBS, 0.75 M
NaCl, pH 7.4, containing 5% NBCS, 5% bovine serum as above. The cut-off value was choosen as twofold the
mean value obtained from nine control wells containingalbumin (BSA), and 0.5% Tween 20, was added and incu-
bated for 1 hr at room temperature. Following three BSA alone (21 0.035 in a representative experiment). Bind-
ing activity for a given peptide was expressed as the O.D.washes, 100 ml of horseradish-peroxidase-conjugated
goat anti-mouse F(ab*)2 (Tago, Burlingame, CA) diluted value/cut-off value (Table 2). The omission of either the core
particles or the monoclonal anti-HBc resulted in O.D. values1/10,000 in the same buffer was added. Plates were incu-
bated for 30 min at 377, washed three times, and a mix- below the cut-off value for all BSA-coupled peptides.
Pre-S domains: Peptides L1, L2, and L3 covering theture of hydrogen peroxide/o-phenylenediamine was
added and left for 30 min in the dark at room temperature. 85 N-terminal amino acids (80%) of pre-S1, as well as
peptide L5 (all 55 amino acids of pre-S2), did not bindColor development was stopped with 2 N H2SO4 and the
optical density was read at 492 nm. Preliminary results to HBV core particles in both assays. Peptide L4, corre-
sponding to the 23 C-terminal amino acids of pre-S1,obtained with the ‘‘L’’ peptides prompted us to synthesize
two additional peptides, L4a and L4b, overlapping pep- was found to bind to HBV core particles in the inhibition
immunoassay (Table 1). Peptide L4b corresponding totide L4. Reduction in the signal was quantified as a per-
centage of inhibition: 100X(1-[OD with peptide/OD with- the 13 C-terminal amino acids of pre-S1 plus the 8 N-
terminal amino acids of pre-S2 bound efficiently to HBVout peptide]) and correlated with increasing peptide con-
centration. The mean percentages of inhibition obtained core particles in the inhibition immunoassay, whereas
peptide L4a had only weak binding affinity. In addition,in four independent experiments with the nine peptides
at three different concentrations (5, 50, and 100 mg/ml) peptide L4b was the only ‘‘L’’ peptide that bound to HBV
core particles in the direct binding assay (Table 2).were determined (Table 1).
We further tested the peptides ability to bind directly to These results suggest that the 13 C-terminal amino
acids of pre-S1 are involved in HBV envelope – core in-HBV core particles by an alternative method based on pep-
tide immobilization to the solid matrix. The direct immobili- teraction.
Recently, Dyson and Murray (20) tested random hexa-zation of free peptides to the ELISA plate resulted in a
complete loss of binding activity for all peptides. However, peptides for their binding properties to recombinant HBV
core particles. Selected hexapeptides were further inves-when peptides were conjugated to bovine serum albumin
(BSA) with carbodiimide as previously described (19), a tigated and a peptide LDPAFR equivalent to positions 19
to 24 of pre-S1 inhibited the binding of HBV cores to thereproducible HBV core binding activity was obtained with
peptides L4b and S2: Dynatech ELISA plates were coated L polypeptide. In contrast, our L1 peptide (aa 1–28 of
pre-S1) containing this 6 amino acids sequence did notwith the different peptides coupled to BSA (or with BSA
alone) at a concentration of 20 mg/ml in 0.05 M bicarbonate bind to HBV core particles in our assays. This discrep-
ancy may be due to the different lengths of the peptidesbuffer (pH 9.6) for 24 hr at 47 (200 ml per well). Plates were
TABLE 1
Binding of HBV Envelope Peptides to HBV Core Particles Tested by Inhibition in a HBc Ag-Specific Immunoassay
Peptides
Concentration L1 L2 L3 L4 L4a L4b L5 S1 S2
5 mg/ml 0 0 0 15 { 3% 4 { 2% 16 { 5% 0 0 38 { 4%
50 mg/ml 0 0 0 28 { 5% 4 { 2% 77 { 2% 0 0 80 { 3%
100 mg/ml 0 0 0 33 { 2% 12 { 4% 91 { 2% 0 0 83 { 7%
Note. The binding was evaluated as the peptides ability to inhibit core particle capture and detection in a specific immunoassay. OD values
given by core particles alone (standardized to 2.5) were compared with OD values for core particles preincubated with various concentrations of
a peptide. Results were expressed as percentages of inhibition: 100 1 (1-[OD with peptide/OD without peptide]). Values reported here represent
the mean percentages and standard deviations of 4 independent experiments performed with the 9 peptides at 3 concentrations (5, 50, and 100
mg/ml). 0, no inhibition.
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TABLE 2
Direct Binding of BSA-Coupled HBV Envelope Peptides to HBV Core Particles
Peptides
L1 L2 L3 L4 L4a L4b L5 S1 S2
0.4 { 0.05 0.51 { 0.03 0.85 { 0.02 0.54 { 0.03 0.68 { 0.03 4.6 { 0.1 0.89 { 0.02 0.52 { 0.02 5.2 { 0.11
Note. The binding was evaluated as the BSA-coupled peptides to directly retain core particles. Results were given as O.D. sample/cut-off value
being twofold the mean O.D. value obtained with BSA alone. Values reported here represent the mean O.D. sample/cut-off and standard deviations
of 3 independent experiments.
or to the different origins of the HBV core particles: re- Deletions in the cytosolic loop of S hamper particle
assembly and secretion (26). In vitro peptide/core bindingcombinant Escherichia coli-derived HBV core particles
were used in the previous study, whereas we used hu- assays are thus very convenient alternatives to cell cul-
ture for exploring the function of this HBV envelope pro-man liver-derived HBV core particles. Our results are
consistent with the data reported by Bruss and Thoms- tein using deletion mutants. We could not, however, in-
vestigate the potential core binding affinity of the type Isen (7), who tested deletion mutants for their ability to
support virion maturation. They showed that the 17 C- signal, also exposed at the cytosolic side of ER in the i-
pre-S form of L, because the peptide covering this do-terminal amino acids of pre-S1 play a key role in virion
morphogenesis. Our study suggests that the 13 C-termi- main was too hydrophobic to be solubilized in the condi-
tions used in our assays.nal amino acids of pre-S1 (PLSPPLRNTHPQA) are a tar-
get for HBV core particles during virion maturation. Inter- In conclusion, our data suggest that both pre-S1 and
S domains of HBV envelope proteins have binding affini-estingly, 8 (62%) of these 13 amino acids are identical
(PPTPPLRDTHPHL) in the woodchuck hepatitis virus ties to HBV core particles in vitro. This dual interaction
of the HBV core with HBV envelope protein domains may(WHV) L protein (21), which is able to replace the HBV L
protein in HBV maturation (22). The pre-S2 domain, as be required for the virion morphogenesis.
represented by the L5 peptide, did not show any binding
affinity to HBV core particles. ACKNOWLEDGMENTS
S domains: Peptide S1 (amino acids 31 to 55 of the
We are indebted to Dr Franc¸oise Aubrit (Diagnostics Transfusion,cytosolic loop of S) did not bind to HBV core particles.
Marnes la Coquette) for her help in synthesizing the 55 aa pre-S2Peptide S2 (amino acids 56 to 80) bound to HBV cores
peptide. This work was supported by an allocation from the French
in both inhibition immunoassay and direct binding assay Ministry of Education (programme ‘‘Virologie Fondamentale’’). F. Pois-
(Tables 1 and 2). Thus a S domain binds to HBV core son was supported by a fellowship provided by the ‘‘Electricite´ & Sante´’’
Institute. C. Hourioux was supported by a fellowship provided by theparticles and may contribute to the virion morphogene-
‘‘Fondation Merieux.’’sis. This may explain why HBV virions lacking C-terminal
pre-S1 sequences have been observed in sera of some
patients (23). Possibly S domain interaction with the HBV REFERENCES
core is sufficient for some virions to be enveloped and 1. Ganem, D., and Varmus, H. E., Annu. Rev. Biochem. 56, 651–693
secreted. This additional interaction with the HBV core (1987).
2. Tiollais, P., Pourcel, C., and Dejean, A., Nature 317, 489–495 (1985).may be provided either by the cytolosic loop of S or by
3. Bruss, V., and Ganem, D., Proc. Natl. Acad. Sci. USA 88, 1059–the i-pre-S form of the L protein which exposes the N
1063 (1991).terminal sequence of S up to signal II on the cytosolic
4. Roingeard, P., Lu, S., Sureau, C., Freschlin, M., Arbeille, B., Essex,
side of ER. However, a specific interaction of S with the M., and Romet-Lemonne, J. L., Hepatology 10, 342–345 (1990).
HBV core may explain why HBV mutants lacking the i- 5. Huovila, A-P. J., Eder, A. M., and Fuller, S. D., J. Cell Biol. 118, 1305–
1320 (1992).pre-S form of L are able to envelop and secrete low
6. Heermann, K. H., Goldmann, U., Schwartz, W., Seyffarth, T., Baumg-levels of virions (24). Furthermore, it has been reported
arten, H., and Gerlich, W. H., J. Virol. 52, 396–402 (1984).that transfected murine fibroblastic LTK cells produce
7. Bruss, V., and Thomssen, R., J. Virol. 68, 1643–1650 (1994).
and secrete HBV-like particles although they barely ex- 8. Ueda, K., Tsurimoto, T., and Matsubara, K., J. Virol. 65, 3521–3529
press the L protein (25). A comparison of the amino acid (1991).
9. Simon, K., Lingappa, V. R., and Ganem, D., J. Cell Biol. 107, 2163–sequence of S between positions 56 to 80 with the corre-
2168 (1988).sponding region of the WHV S protein (21) shows a 72%
10. Heermann, K. H., and Gerlich, W. H., In ‘‘Molecular Biology of theidentity: QTCKHLPTSCPPTCNGFRWMYLRRF. This may
Hepatitis B Virus’’ (A. McLachlan, Ed.), pp. 109–143. CRC Press,
be of importance, since WHV S protein is able to substi- Boca Raton, FL, 1991.
tute for its HBV conterpart in cooperation with HBV L for 11. Bruss, V., Lu, X., Thomssen, R., and Gerlich, W. H., EMBO J. 13,
2273–2279 (1994).virion maturation (22).
AID VY 8367 / 6a27$$$322 01-02-97 14:14:45 vira AP: Virology
120 SHORT COMMUNICATION
12. Ostapchuck, P., Hearing, P., and Ganem, D., EMBO J. 13, 1048– 20. Dyson, M. R., and Murray, K., Proc. Natl. Acad. Sci. USA 92, 2194–
2198 (1995).1057 (1994).
13. Prange, R., and Streeck, R. E., EMBO J. 14, 247–256 (1995). 21. Cohen, J. I., Miller, R. H., Rosenblum, B., Denniston, K., Gerin, J. L.,
and Purcell, R. H., Virology 162, 12–20 (1988).14. Klingmuller, U., and Schaller, H., J. Virol. 67, 7414–7422 (1993).
15. Galibert, F., Mandart, E., Fitoussi, F., Tiollais, P., and Charnay, P., 22. Gerhardt, E., and Bruss, V., J. Virol. 69, 1201–1208 (1995).
23. Gerken, G. D., Kremsdorf, D., Capel, F., Petit, M. A., Dauguet, C.,Nature 281, 646–650 (1979).
16. Merrifield, R. B., J. Am. Chem. Soc. 85, 2149–2154 (1963). Manns, M. R., Meyer zum Bu¨schenfelde, K., and Brechot, C.,
Virology 183, 555–565 (1991).17. Fauconnet, M., and Richemont, J., Anal. Biochem. 91, 403–409
(1978). 24. Bruss, V., and Vieluf, K., J. Virol. 69, 6652–6657 (1995).
25. Seifer, M., Heermann, K. H., and Gerlich, W. H., Virology 179, 300–18. Roingeard, P., Romet-Lemonne, J-L., Leturcq, D., Goudeau, A., and
Essex, M., Virology 179, 113–120 (1990). 311 (1990).
26. Prange, R., Nagel, R., and Streeck, R. E., J. Virol. 66, 5832–584119. Poisson, F., Baillou, A., Dubois, F., Janvier, B., Roingeard, P., and
Goudeau, A., J. Clin. Microbiol. 31, 2343–2349 (1993). (1992).
AID VY 8367 / 6a27$$$323 01-02-97 14:14:45 vira AP: Virology
